We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Port Erin | LSE:PEBI | London | Ordinary Share | IM00B6QH1J21 | ORD 0.0001P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.50 | 4.00 | 5.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMPEBI
RNS Number : 0094U
Port Erin Biopharma Investments Ltd
19 October 2017
19 October 2017
Port Erin Biopharma Investments Limited
(the "Company")
Net Asset Value calculation to 30 September 2017
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at closing on 30 September 2017 was 9.20 pence per share, including un-invested cash of GBP634,765. The portfolio is valued under IFRS at bid price.
Net Assets stand at GBP2.1 million including investments of GBP1.3 million. This quarter's NAV represents a decrease of 1.6% from the previous valuation of 9.35 pence per share, which included un-invested cash of GBP875,885. No additional management fee is due to Shellbay Investments Limited.
Of our principal investments: Regent Pacific Group Limited announced in August 2017 that the commercial launch of their flagship product, Fortacin(TM), will begin in early 2018; Summit Therapeutics PLC announced further positive data for the Phase 2 clinical trial with their selective antibiotic ridinilazole; and SalvaRx Group PLC announced in September 2017 that its wholly owned subsidiary had formed a joint venture with Immunova LLC to develop selective nanomedicine delivery, potentially minimising negative side-effects that patients experience under traditional therapies. We continue to be very positive in our assessment of our portfolio's prospects."
Hot Features
Premium
Unaudited to
30 September 2017
GBP
Fixed Assets
Investments 1,304,740
Current Assets
Loan receivable 200,000
Sundry Debtors 23,287
Uninvested cash 634,756
Current Liabilities
Creditors: amounts due (27,880)
------------------
2,134,903
Capital and Reserves
Share Capital 23
Share Premium 1,890,142
Reserves 244,747
------------------
2,134,912
Shares in Issue 23,195,558
Net Asset Value per share 9.20 pence
Portfolio Details
Investments as at 30 September Value % of Total Portfolio 2017 -------------------------------- ------------- -------------------- Regent Pacific Group Limited GBP378,056 28.98% Summit Therapeutics PLC GBP225,576 17.29% SalvaRx Holdings PLC GBP59,259 4.54% Other quoted holdings GBP36,726 2.81% Other unquoted holdings GBP605,123 46.38% Total GBP1,304,740 100.00% -------------------------------- ------------- --------------------
For further information, please contact:
Port Erin Biopharma Investments Northland Capital Partners Peterhouse Capital Limited
Limited Limited
The Company Nomad and Broker Broker
Denham Eke Matthew Johnson / David Lucy Williams
+44 (0) 1624 639396 Hignell +44 (0) 207 469 0936
+44 (0) 203 861 6625
This information is provided by RNS
The company news service from the London Stock Exchange
END
NAVGMMMGNRGGNZM
(END) Dow Jones Newswires
October 19, 2017 02:00 ET (06:00 GMT)
1 Year Port Erin Chart |
1 Month Port Erin Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
